natgillin/translations-raw huggingface dataset:
cancer, Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, an autoimmune disease, a viral infection, a neurodegenerative disorder, a disorder associated with thymocyte apoptosis, or a proliferative disorder; hematopoietic disorders, in particular, acute-myelogenous leukemia (AML), acute-promyelocytic leukemia (APL), and acute lymphocytic leukemia (ALL); 
karcinoma, Alzheimerove bolesti, restenoze, angiogeneze, glomerulonefritisa, citomegalovirusa, HIV-a, herpesa, psorijaze, ateroskleroze, alopecije, autoimunog oboljenja, virusne infekcije, neurodegenerativnog poremećaja, poremećaja povezanog s apoptozom timocita, ili proliferativnog poremećaja; hematološkog poremećaja, poglavito, akutne mijelogene leukemije (AML), akutne promijelocitne leukemija (APL), i akutne limfocitne leukemije (ALL);
pancreatic, prostate, or ovarian cancer. 
karcinoma pankreasa, prostate, ili jajnika.
A benzopyran derivative of formula (I) or (II), or pharmaceutical acceptable salt thereof wherein 
Derivat benzopirana formule (I) ili (II), ili njegove farmaceutski prihvatljive soli [image] naznačen time, da
is hydrogen atom, 
je vodikov atom.
is a C6-14 aryl group which may be arbitrarily substituted with 1 to 3 R10; a C2-9 heteroaryl group which may be arbitrarily substituted with 1 to 3 R10; a C2-4 alkyl group; C3-8 cycloalkyl group, C3-8 cycloalkenyl group which may be arbitrarily substituted with halogen atom, carboxy group or hydroxy group; 
je C6-14 arilna skupina koja može biti proizvoljno supstituirana sa 1 do 3 R10; C2-9 heteroarilna skupina koja može biti proizvoljno supstituirana sa 1 do 3 R10; C2-4 alkilna skupina; C3-8 cikloalkilna skupina, C3-8 cikloalkenilna skupina koja može biti proizvoljno supstituirana s atomom halogena, karboksi skupinom ili hidroksi skupinom;
is a halogen atom, a hydroxy group or an amino group; 
je atom halogena. hidroksi skupina ili amino skupina;
and wherein the ring structure A is 
i gdje struktura prstena A je [image]
R13, R14 and R15 are independently of each other hydrogen atom, halogen atom, cyano group or C1-6 alkyl group which may be substituted by a hydroxy group or a carboxy group; 
R13, R14 i R15 su neovisno jedan od drugoga vodikov atom, atom halogena, cijano skupina ili C1-6 alkilna skupina koja može biti supstituirana s hidroksi skupinom ili karboksi skupinom;
is hydrogen atom, halogen atom, C1-6 alkyl group which may be substituted by a hydroxy group; 
je vodik atom, atom halogena, C1-6 alkilna skupina koja može biti supstituirana hidroksi skupinom;
is hydrogen atom, halogen atom, C1-6 alkyl group which may be substituted by a hydroxy group. 
R1:v je vodikov atom, atom halogena, C1-6 alkilna skupina koja može biti supstituirana hidroksi skupinom.
the ring structure A is wherein 
struktura prstena A je [image] gdje
The adapter (60) of claim 1, wherein the first retaining member comprises at least one inwardly extending first projection (78). 
Adapter (60) prema patentnom zahtjevu 1, naznačen time, da prvi zadržni element sadrži barem jedno prvo izbočenje (78) koje se pruža prema unutra.
The adapter (60) of claim 6, wherein the second retaining member comprises at least one inwardly extending second projection (92) disposed on the outer periphery of the flange (74). 
Adapter (60) prema patentnom zahtjevu 6, naznačen time, da drugi zadržni element sadrži barem jedno drugo izbočenje (92) koje se pruža prema unutra, smješteno na vanjskom obodu prirubnice (74).
a shell (12) defining an interior chamber (20) having an opening; and a cap (24) hermetically sealing the opening. 
vanjsku ljusku (12) koja određuje unutarnju komoricu (20) s otvorom; i kapicu (24) koja hermetički brtvi otvor.
The assembly of claim 19, wherein the chamber (20) contains multiple doses of a component, such as an influenza vaccine. 
Sklop prema patentnom zahtjevu 19, naznačen time, da komorica (20) sadrži više doza sastojka, kao što je cjepivo protiv gripe.
a housing (32); and a piercing thorn (34), the thorn (34) protruding centrally and perpendicularly from the housing (32). 
kućište (32); i probojni trn (34), kod čega trn (34) strši centralno i okomito iz kućišta (32).
The assembly of claim 23, wherein said predetermined position comprises the thorn (32) of the withdrawal spike (30) being inserted through the vial cap (24) by a predetermined distance. 
Sklop prema patentnom zahtjevu 23, naznačen time, da navedeni predodređeni položaj sadrži trn (32) ekstrakcijskog šiljka (30) koji je uveden kroz kapicu (24) bočice za predodređenu duljinu.
providing a multidose vial (10) containing the component; 
priprema višedozne bočice (10) koja sadrži sastojak;
fitting the adapter (60) onto the multidose vial (10); and fitting the withdrawal spike (30) onto the adapter (60). 
pričvršćivanje adaptera (60) na višedoznu bočicu (10); i pričvršćivanje ekstrakcijskog šiljka (30) na adapter (60).
engaging the camming surface of the or each first projection (78) with the vial cap (24); 
zahvaćanje nazubljene plohe tog ili svakog prvog izbočenja (78) s kapicom (24) bočice;
The method of any of claims 26 to 29, wherein the component comprises a vaccine, such as an influenza vaccine. 
Postupak prema bilo kojem od patentnih zahtjeva 26 do 29, naznačen time, da sastojak sadrži cjepivo, kao što je cjepivo protiv gripe.
A transdermal hydroalcoholic gel composition for use in the treatment of type-2 diabetes in a subject in need thereof, wherein the transdermal hydroalcoholic gel composition comprises: 
Hidroalkoholni sastav gela za transdermalnu uporabu u liječenju dijabetesa tipa-2 kod subjekta u potrebi od toga, naznačen time, što transdermalni hidroalkoholni sastav gela sadrži:
0.1% to 5% (w/w) penetration enhancing agent; 
,1% do 5% (w / w) sredstva povećanja prodiranja;
the balance water; wherein the serum testosterone concentration in the subject is at least 600 ng/dl to 1050 ng/dl after at least 30 days of daily administration of the composition. 
ravnotežu vode; pri čemu je koncentracija seruma testosterona kod subjekta najmanje 600 ng / dl do 1050 ng / dl nakon svakodnevne primjene sastava najmanje 30 dana.
The transdermal hydroalcoholic gel composition according to claim 1 wherein the transdermal hydroalcoholic gel composition comprises: 
Transdermalni hidroalkoholni sastav gela u skladu sa zahtjevom 1, naznačen time, što transdermalni hidroalkoholni sastav gela sadrži:
the balance purified water. 
ravnotežu pročišćene vode.
The transdermal hydroalcoholic gel composition according to claim 1 or 2, wherein the composition comprises about 1% (w/w) of testosterone. 
Transdermalni hidroalkoholni sastav gela u skladu sa zahtjevom 1 ili 2, naznačen time, što sastav sadrži oko 1% (w / w) testosterona.
The transdermal hydroalcoholic gel composition according to any one of claims 1 to 3, wherein the penetration enhancing agent is selected from the group consisting of a C8-C22 fatty acid, a C8-C22 fatty alcohol, a lower alkyl ester of a C8-C22 fatty acid, a di(lower)alkyl ester of a C6-C22 diacid, a monoglyceride of a C8-C22 fatty acid, a tetrahydrofurfuryl alcohol polyethylene glycol ether, a polyethylene glycol, a propylene glycol, a 2-(2-ethoxyethoxy) ethanol, a diethylene glycol monomethyl ether, an alkylaryl ether of polyethylene oxide, a polyethylene oxide monomethyl ether, a polyethylene oxide dimethyl ether, a dimethyl sulfoxide, a glycerol, an ethyl acetate, an acetoacetic ester, a N-alkylpyrrolidone, a terpene, isopropyl myristate and combinations thereof. 
Transdermalni hidroalkoholni sastav gela u skladu sa bilo kojim zahtjevom 1 do 3, naznačen time, što sredstvo povećanja prodiranja je odabrano iz skupine koja se sastoji od C8-C22 masnih kiselina, C8-C22 masnih alkohola, nižih alkil estera od C8-C22 masnih kiselina, di (donji) alkil estera od C6-C22 diacida, monoglicerida od C8-C22 masnih kiselina, alkohola tetrahidrofurfuril polietilen glikol etera, polietilen glikola, propilen glikola, 2-(2-etoksietoksi)etanola, dietilen glikol monometil etera, alkilaril etera od polietilen oksida, polietilen oksida monometil etera, polietilen oksida dimetil etera, dimetil sulfoksida, glicerola, etil acetata, acetoacetik estera, N-alkilpirolidona, terpena, izopropil miristata i njihove kombinacije.
The transdermal hydroalcoholic gel composition of claim 4, wherein the penetration enhancing agent is isopropyl myristate. 
Transdermalni hidroalkoholni sastav gela u skladu sa zahtjevom 4, naznačen time, što sredstvo povećanja prodiranja je izopropil miristat.
The transdermal hydroalcoholic gel composition according to any one of claims I to 5, wherein the thickening agent is polyacrylic acid. 
Transdermalni hidroalkoholni sastav gela u skladu sa bilo kojim zahtjevom 1 do 5, naznačen time, što sredstvo zadebljanja je poliakrilna kiselina.
The transdermal hydroalcoholic gel composition according to any one of claims 1 to 6, wherein the transdermal hydroalcoholic gel composition comprises 45% to 90% ethanol or isopropanol. 
Transdermalni hidroalkoholni sastav gela u skladu sa bilo kojim zahtjevom 1 do 6, naznačen time, što transdermalni hidroalkoholni sastav gela sadrži 45% do 90% etanola ili izopropanola.
The transdermal hydroalcoholic gel composition or claim 1, wherein the transdermal hydroalcoholic gel composition comprises: 
Transdermalni hidroalkoholni sastav gela ili zahtjev 1, naznačen time, što transdermalni hidroalkoholni sastav gela sadrži:
The transdermal hydroalcoholic gel composition according to any one of claims 1 to 9 wherein the transdermal hydroalcoholic gel composition is capable of releasing testosterone after applying the composition to the skin at a rate and duration that delivers at least 10 µg per day of testosterone to the blood serum of the subject. 
Transdermalni hidroalkoholni sastav gela u skladu sa bilo kojim zahtjevom 1 do 9 naznačen time, što je transdermalni hidroalkoholni sastav gela sposoban oslobađati testosterone nakon primjene sastava na kožu po omjerima i trajanju koja isporučuju dnevno najmanje 10 μg testosterona u krvi seruma subjekta.
The transdermal hydroalcoholic gel composition according to any one of claims 1 to 10, wherein the serum testosterone concentration is at least 700 ng/dl serum to 1050 ng/dl serum. 
Transdermalni hidroalkoholni sastav gela u skladu sa bilo kojim zahtjevom 1 do 10, naznačen time, što je koncentracija seruma testosterona najmanje 700 ng / dl seruma do 1050 ng / dl seruma.
The transdermal hydroalcoholic gel composition according to any one of claims 1 to 11 wherein an amount of the transdermal hydroalcoholic gel composition is administered to an area of skin of the subject, which delivers a therapeutically-effective amount of testosterone to the blood serum of the subject. 
Transdermalni hidroalkoholni sastav gela u skladu sa bilo kojim zahtjevom 1 do 11 naznačen time, što je količina transdermalnog hidroalkoholnog sastava gela primjenjivana na područje kože subjekta, koja isporučuje terapijski učinkovitu količinu testosterona u krvi seruma subjekta.
The transdermal hydroalcoholic gel composition according to any one of claims I to 12, wherein the transdermal hydroalcoholic get composition is provided to the subject for daily administration in a 0.1 g to a 10 g dose. 
Transdermalni hidroalkoholni sastav gela u skladu sa bilo kojim zahtjevom 1 do 12, naznačen time, što je transdermalni hidroalkoholni sastav gela omogućen subjektu za svakodnevnu primjenu u dozi 0,1 g do 10 g.
The transdermal hydroalcoholic gel composition according to any one of claims 1 to 14, wherein said composition is administered once, twice, or three times daily for at least 7 days. 
Transdermalni hidroalkoholni sastav gela u skladu sa bilo kojim zahtjevom 1 do 14, naznačen time, što je navedeni sastav primjenjivan jednom, dvaput ili triput svakodnevno u najmanje 7 dana.
The use according to claim 4, wherein the disease, disorder or condition is anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias, including social phobias, obsessive-compulsive disorder, and generalized or substance-induced anxiety disorder. 
Uporaba prema zahtjevu 4, naznačena time, što je bolest, poremećaj ili stanje depresija, kao što je panični poremećaj sa ili bez agorafobije, agorafobija bez povijesti paničnog poremećaja, strah od životinja i druge fobije, društvena fobija, opsesivno-kompulzivni poremećaj i opći ili posebni poremećaj uslijed depresije.
The compound according to claim 7 wherein the disease, disorder or condition is anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias, including social phobias, obsessive-compulsive disorder, and generalized or substance-induced anxiety disorder. 
Spoj u skladu sa zahtjevom 7, naznačen time, što je bolest, poremećaj ili stanje depresija, kao što je panični poremećaj sa ili bez agorafobije, agorafobija bez povijesti paničnog poremećaja, strah od životinja i druge fobije, društvena fobija, opsesivno-kompulzivni poremećaj i opći ili posebni poremećaj uslijed depresije.
A process for preparing an influenza vaccine from influenza virus that is grown in a culture of a Vero cell line, comprising a step in which seed virus and/or the vaccine and/or the culture is tested for the presence of an infectious agent that can grow in said cell line but that does not grow in embryonated hen eggs wherein said infectious agent is one or more of the following pathogens: Pneumovirinae; Metapneumoviruses of the Paramyxoviridae family; Rubulaviruses of the Paramyxoviridae family; Coronaviridae; Rhinoviruses of the Picornaviridae family; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echoviruses; Coxsackieviruses of the Enteroviruses of the Picornaviridae family; Rotavirus; Porcine picornaviruses; Parvovirus; Circovirus; Chlamydia bacteria; mammalian Reoviridae. 
Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi Vero stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Pneumovirinae; Metapneumovirusi iz familije Paramyxoviridae; Rubulavirusi iz familije Paramyxoviridae; Coronaviridae; Rhinovirusi iz familije Picornaviridae; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echovirusi; Coxsackievirusi od Enterovirusa iz familije Picornaviridae; Rotavirus, svinjski picornavirusi; Parvovirus; Circovirus; bakterija Chlamydia; Reoviridae kod sisavaca.
The process of claim 1 wherein the infectious agent is one or more of the following pathogens: human metapneumovirus (HMPV); Mumps virus; respiratory syncytial virus (RSV); human coronaviruses; SARS coronavirus; M-strains of Rhinovirus; swine vesicular virus (SVDV); canine Parovirus; Teschen-Talfan virus; C. trachomatis; C . pneumoniae; C. psittaci. 
Postupak prema patentnom zahtjevu 1, naznačen time, da infekcijski agens jest jedan ili više od sljedećih patogena: humani metapneumovirus (HMPV); virus mumpsa; respiratorni sincicijski virus (RSV); humani coronavirusi; SARS corona virus; M sojevi Rhinovirusa; svinjski vezikularni virus (SVDV); pseći Parovirus, Teschen-Talfan virus; C. trachomatis; C. pneumoniae; C. psittaci.
The process of claim 1 further comprising one or more of the following steps: a step of inactivation; a step of mixing three virus strains to make a trivalent vaccine; a step of formulating the vaccine for injection; a step of combining the vaccine with an adjuvant; a step of measuring HA content; a step of adjusting HA content e.g. 
Postupak prema patentnom zahtjevu 1, naznačen time, da nadalje sadrži jedan ili više od sljedećih stupnjeva: stupanj inaktivacije; stupanj miješanja tri virusna soja da se napravi trovalentno cjepivo; stupanj formuliranja cjepiva za injektiranje; stupanj združivanja cjepiva s adjuvansom; stupanj mjerenja sadržaja HA; stupanj podešavanja sadržaja HA, na pr.
by dilution; a step of adding a preservative; a step of removing residual host cell nucleic acids. 
razrjeđivanjem; stupanj dodavanja konzervansa; stupanj odstranjivanja rezidualnih nukleinskih kiselina koje pripadaju stanici domaćina.
The process of any of the preceding claims, wherein testing is performed at one of the following stages: viral infection, growth stages, viral harvest, viral processing, splitting, surface protein extraction, vaccine formulation, vaccine packaging. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se testiranje provodi kod jednog od sljedećih stupnjeva: virusna infekcija, stadiji rasta, prikupljanje virusa, procesuiranje virusa, razdvajanje, ekstrakcija membranskih proteina, formuliranje cjepiva, pakiranje cjepiva.
A pharmaceutical tablet or tablet layer comprising the angiotensin II receptor antagonist telmisartan in amorphous form, a basic agent and sorbitol, characterized in that the sorbitol has a specific surface area of between 0.75-3.5 m2/g, preferably 1.4-3.0 m2/g and most preferred 2.0-2.5 m2/g. 
Farmaceutska tableta ili sloj tablete koji sadrže antagonist angiotenzin II receptora telmisartan u amorfnom obliku, bazično sredstvo i sorbitol, naznačeni time, da sorbitol ima specifičnu površinu između 0.75–3.5 m2/g, povoljnije je 1.4–3.0 m2/g i najpovoljnije je 2.0–2.5 m2/g.
A process for preparing an influenza vaccine from influenza virus that has been grown in a culture of a mammalian cell line, comprising a step in which the seed virus and/or the vaccine and/or the culture is tested for the presence of an infectious agent that can grow in said cell line but that does not grow in embryonated hen eggs, wherein the infectious agent is selected from the group consisting of: Pneumovirinae; mammalian Reoviridae; Birnaviridae; Rubulaviruses of the Paramyxoviridae family; Coronaviridae; Rhinoviruses of the Picornaviridae family; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echoviruses; Coxsackieviruses of the Enteroviruses of the Picornaviridae family; Rotavirus; Porcine picornaviruses; Parvovirus; Circovirus; and Chlamydia bacteria. 
Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi Vero stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Pneumovirinae; Metapneumovirusi iz familije Paramyxoviridae; Rubulavirusi iz familije Paramyxoviridae; Coronaviridae; Rhinovirusi iz familije Picornaviridae; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echovirusi; Coxsackievirusi od Enterovirusa iz familije Picornaviridae; Rotavirus, svinjski picornavirusi; Parvovirus; Circovirus; bakterija Chlamydia; Reoviridae kod sisavaca.
C6 cell line. The process of claim 1 further comprising one or more of the following steps: a step of inactivation; a step of mixing three virus strains to make a trivalent vaccine; a step of formulating the vaccine for injection; a step of combining the vaccine with an adjuvant; a step of measuring HA content; a step of adjusting HA content e.g. by dilution; a step of adding a preservative; a step of removing residual host cell nucleic acids. 
Postupak prema patentnom zahtjevu 1, naznačen time, da nadalje sadrži jedan ili više od sljedećih stupnjeva: stupanj inaktivacije; stupanj miješanja tri virusna soja da se napravi trovalentno cjepivo; stupanj formuliranja cjepiva za injektiranje; stupanj združivanja cjepiva s adjuvansom; stupanj mjerenja sadržaja HA; stupanj podešavanja sadržaja HA, na pr. razrjeđivanjem; stupanj dodavanja konzervansa; stupanj odstranjivanja rezidualnih nukleinskih kiselina koje pripadaju stanici domaćina.
An engine (100) comprising: 
Motor (100), koji uključuje:
a crankshaft (108) rotatable about a crankshaft axis (110); 
koljenasto vratilo (108) koje se okreće oko osi koljenastog vratila (110);
Glucose isomerase for use in the therapy of fructose intolerance, provided that the glucose isomerase is not used in combination with 5-D-fructose dehydrogenase for said therapy. 
Glukoza izomeraze za uporabu u liječenju ili dijagnozi intolerancije fruktoze, naznačena time, što je omogućeno da se glukoza izomeraze ne koristi u kombinaciji sa 5-D-fruktozom dehidrogenaze.
An intraocular lens injector cartridge (10), comprising: 
Patrona intraokularne lećne štrcaljke (10), koja obuhvaća:
a body (12) having an internal lumen (15); 
tijelo (12) koje ima unutarnje svjetlo (15);
a tubular nozzle (14) having an outer wall (36) and an opening (18), the nozzle projecting distally from the body, the opening being fluidly connected to the internal lumen of the body; characterized by 
cjevastu brizgalicu (14) koja ima vanjsku stijenku (36) i otvor (18), dok je brizgalica izbočena distalno od tijela, a otvor je fluidno povezan na unutarnje svjetlo tijela;
The cartridge of claim 1, wherein the canopy (20) entirely surrounds the opening (18). 
Patrona prema zahtjevu 1, naznačena time, da streha (20) potpuno opkoljava otvor (18).
The cartridge of any one of claims 1 to 6, wherein the peripheral protrusion (22) comprises a stop. 
Patrona prema bilo kojem zahtjevu 1 do 6, naznačena time, da rubna izbočina (22) sadrži završetak.
The process of claim 1, wherein the solvent is an alcohol, preferably selected from the group consisting of methanol, ethanol and isopropanol. 
Postupak prema zahtjevu 1, naznačen time da je otapalo alkohol, poželjno odabrano iz skupine koja se sastoji od metanola, etanola i izopropanola.
The process of claim 1, wherein the opioid analgesic is selected from the group consisting of oxycodone, hydromorphone, hydrocodone, codeine, morphine, buprenorphine, pharmaceutically acceptable salts thereof and mixtures thereof. 
Postupak prema zahtjevu 1, naznačen time da je opioidni analgetik odabran iz skupine koja se sastoji od hidrokodona ili kodeina, njihovih farmaceutski prihvatljivih soli i njihovih smjesa.
The process of claim 1, wherein the hydrogenation produces an opioid analgesic composition having an a, β-unsaturated ketone level of less than 25 ppm, less than 15 ppm, less than 10 ppm, or less than 5 ppm. 
Postupak prema zahtjevu 1, naznačen time da hidrogeniranje proizvodi sastav opioidnog analgetika koji ima sadržaj a, β- nezasićenog ketona manji od 25 ppm, manji od 15 ppm, manji od 10 ppm, ili manji od 5 ppm.
R is selected from the group consisting of hydrogen; C1-8 alkyl; C3-6cycloalkyl; (C3-6)cycloalkyl(C1-3)alkyl; phenyl(C1-3)alkyl; and phenyl(C1-3)alkyl substituted with 1-3 members of the group consisting of C1-8 alkyl, trifluoromethyl, nitro, dialkylamino and cyano; 
R je odabran iz skupine koja se sastoji od vodika; C1-8 alkila; C3-6 cikloalkila; (C3-6)cikloalkil(C1-3) alkila; fenil(C1-3)alkila; i fenil(C1-3)alkila supstituiranog s 1-3 člana skupine koja se sastoji od C1-8 alkila, trifluorometila, nitro, dialkilamino i cijano;
A composition suitable for control of diseases caused by phytopathogens comprising 
Pripravak pogodan za kontrolu bolesti uzrokovanih fitopatogenima koji se sastoji od:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.